UCB Proposes a Dividend of €1.45 per Share and Renews Its Leadership
UCB SA has announced the convening of its ordinary and extraordinary general meeting on April 30, 2026. The pharmaceutical group will submit for shareholder approval its 2025 accounts, the renewal of director mandates, and several resolutions related to its financing powers.
The ordinary general meeting will review the annual accounts of UCB SA and the consolidated accounts of the group for the fiscal year ended December 31, 2025. The Board of Directors proposes the approval of the annual accounts and the allocation of results, including the distribution of a gross dividend of €1.45 per share. Shareholders will also vote on the 2025 compensation report, on the discharge of the directors and the commissioner (Forvis Mazars) for the past year. The renewal of two director mandates will be put to vote: that of Jean-Christophe Tellier, CEO and executive director, and that of Cédric van Rijckevorsel, director representing the reference shareholder. Both would be renewed for a term of four years, until the general meeting of 2030. The mandate of Kay Davies, independent director, is not being renewed; the Board thanks her for her contribution over the past twelve years.
Deliberations of the Extraordinary General Meeting
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The extraordinary general meeting will decide on the renewal of the Board of Directors' powers regarding authorized capital for an additional two years. The Board would be authorized to increase the capital by up to 5% in the event of limitation or elimination of preemptive rights of shareholders, or by 10% without limitation of preemptive rights. The meeting will also review the renewal of the approval of the change of control clause of the EMTN (Euro Medium Term Note) program for a duration of twelve months, allowing bondholders to demand repayment of their securities in the event of a change of control of the group. Finally, the renewal of the authorization to acquire own shares up to 10% of the total number of shares, for a duration of two years starting from July 1, 2026, will be proposed. This authorization could be used particularly in the context of long-term incentive plans for employees and management of the group.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 4 270 millions d'euros
Quarterly revenue: 4 270 millions d'euros
Revenue growth: 22,5 %
EBITDA: 1 685 millions d'euros
EBITDA margin: 40,7 %
Net income: 1 111 millions d'euros
2 821 millions d'euros
Guidance from the release
Based on the continued strong growth, revenue is expected to grow in the low-teens to mid-teens percentage range; Reflecting our strong execution and confidence in the outlook
Risks mentioned
Perte d'exclusivité de BRIVIACT aux États-Unis depuis février 2026 et en Europe attendue en août 2026
Ventes de VIMPAT au Japon affectées par l'arrivée de génériques fin 2025
Expiration en 2026 de la protection brevetaire de CIMZIA au Japon
Opportunities identified
Objectif de ventes maximales de BIMZELX relevé à au moins 7 milliards d'euros
Supériorité de BIMZELX sur risankizumab dans le rhumatisme psoriasique (étude BE BOLD)
FINTEPLA déposé dans le syndrome CDKL5 auprès de la FDA et de l'EMA, Phase 3 lancée dans le syndrome de Rett
Outlook / guidance
Management commentary: revenue is expected to grow in the low-teens to mid-teens percentage range at constant exchange rates (CER). Adjusted EBITDA² is expected to grow in the mid-teens to low-twenties percentage range at CER. Excluding other operating one-offs in 2025, adjusted EBITDA² growth is expected to be in the mid-twenties to low-thirties percentage range at CER.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.